On September 21, 2016, the Board of Directors of Stereotaxis Inc. approved an increase in the size of the Board from eight to nine Directors. On September 22, 2016, Euan S. Thomson, resigned as a Class II Director of the company. Effective September 29, 2016, Joseph D. Keegan, resigned as a Class II Director of the company. The resignations were not due to any disagreement with the company. The Board appointed each of David Fischel, Joseph Kiani and Arun Menawat to the Board. Dr. Menawat was appointed as a Class I Director with a term expiring at the 2017 annual meeting of shareholders. Mr. Fischel and Mr. Kiani were appointed as Class II Directors with a term expiring at the 2018 annual meeting of shareholders.
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation, fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Companyâs primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.
STEREOTAXIS, INC. 
